Allurion Technologies Delisted from NYSE, Now Trading OTCID; Company Appeals and Plans Relisting

summarizeSummary

Allurion Technologies has been delisted from the NYSE and its shares are now trading on the OTCID Market, following non-compliance with market capitalization rules; the company is appealing the decision and has a plan to relist.

check_boxKey Events

• NYSE Delisting Confirmed

  On March 6, 2026, the NYSE notified Allurion Technologies of its determination to delist the company's common stock and warrants due to non-compliance with the $15 million average global market capitalization rule.

• Trading Suspended and Moved to OTCID

  Trading on the NYSE was suspended after market close on March 6, 2026, with the common stock now trading on the OTCID Market.

• Company Appeals Delisting

  Allurion has appealed the NYSE's delisting determination and intends to apply to list on a higher-tier market operated by the OTC Market Group, Inc. or NYSE American.

• Plan to Regain Compliance

  The company is executing a detailed plan, catalyzed by recent FDA approval, to strengthen its balance sheet and fund commercialization, aiming to regain compliance with NYSE standards or relist on NYSE American.

auto_awesomeAnalysis

This 8-K confirms Allurion Technologies' delisting from the New York Stock Exchange (NYSE) due to failing to maintain the minimum $15 million average global market capitalization. Trading in the company's common stock and warrants was suspended on March 6, 2026, and has transitioned to the OTCID Market. While the company has appealed the NYSE's decision and is executing a plan, including leveraging a recent FDA approval, to regain compliance or relist on NYSE American or a higher OTC tier, the immediate impact is a significant reduction in liquidity and investor visibility. This event signals severe financial distress and poses substantial risks to shareholders.